Inside a cell therapy manufacturing facility: How Iovance turns a patient’s immune cells into treatment

Rusty Konkol wanted to hug everyone he saw during his tour of Iovance Biotherapeutics’ Navy Yard manufacturing facility. The ...
Labroots

Automated, High Purity Cell Isolation for Efficient Cell Therapy Manufacturing

In cell therapy applications, commonly employed cell purification platforms for large-scale isolation of immune or stem cells separate cells based on a single cell surface antigen. Enrichment based on ...
Hosted on MSN

Lineage Cell Therapeutics outlines manufacturing milestone and anticipates OpRegen 36-month data update while advancing OPC1 clinical plans

CEO Brian Culley highlighted the progress of OpRegen, noting its differentiation from current anti-complement therapies for dry AMD. He emphasized, “OpRegen has shown evidence of both anatomical and ...
BioSpace

As CGT Manufacturing Scales Up, Automation and Collaboration Become Essential

As cell and gene therapy developers face rising pressure to produce therapies faster and at lower cost, the industry is ...

BioOra and Octane Biotech Sign Letter of Intent to Expand Cell Therapy Manufacturing Using the Cocoon(R) Platform

Collaboration builds on CAR-T commercialization in New Zealand and supports expansion across Australia, North America and other international markets.Wellington, New Zealand and Kingston, ...

J&J's Cell Therapy Factory Bet Positions Manufacturing Scale as Its Next Competitive Moat

Johnson & Johnson bets $1B on a Pennsylvania cell therapy plant as earnings momentum, pipeline deals, and MedTech approvals ...
Seeking Alpha

Lineage Cell Therapeutics outlines manufacturing milestone and anticipates OpRegen 36-month data update while advancing OPC1 clinical plans

Management continues to anticipate the presentation of three-year OpRegen trial data in June 2025, with Culley expressing hope it will “provide additional conviction in our approach.” There remains no ...